Pharma Major Lupin’s US subsidiary, Lupin Pharmaceuticals Inc has launched its Amlodipine and Valsartan Tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation’s Exforge tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg strengths. Lupin had received final approval from the United States Food and Drug Administration (FDA) for the product.
Lupin’s Amlodipine and Valsartan Tablets is the combination tablet of Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB). Lupin’s Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Exforge Tablets had U.S sales of $ 414.9 million (IMS MAT December, 2014).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: